Clinical trial
Identification and Evaluation of Patients at Risk of Developing Cardiotoxicity After Receiving Chemotherapy for Breast Cancer, Lymphoma or Leukemia
NCT04541212 is registered in ClinicalTrials.gov with Montreal Heart Institute as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Identification and Evaluation of Patients at Risk of Developing Cardiotoxicity After Receiving Chemotherapy for Breast Cancer, Lymphoma or Leukemia
- Lead sponsor
- Montreal Heart Institute
- Phase
- Observational
- Overall status
- Active, not recruiting
- Start date
- December 2, 2021
- Completion date
- September 30, 2027
- Enrollment
- 169 (actual)
- Sites
- 6
Conditions
As the registry lists them; a condition with its own page is linked.